undamentalytics Newsletter
Sign in

Orchestra Biomed Holdings, Inc. key statistics and ratios

In fiscal 2025, Orchestra Biomed Holdings, Inc. had return on equity of -121.8% and a net margin of -157.4%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Net margin−951.3%<−999%<−999%−157.4%−184.6%
Return on equity−64.0%−81.5%−120.8%−121.8%−162.0%
Return on assets−35.2%−51.5%−71.2%−55.2%−51.2%
R&D as % of revenue621.1%>999%>999%173.8%197.7%
SG&A as % of revenue397.2%734.0%907.2%80.4%83.2%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

4 of 6 checks passed · June 30, 2026
What it owns · $116m
Short-term assets $111mLonger-term assets $4m
What it owes, and who funded it · $106m
Short-term liabilities $13mLonger-term liabilities $73mShareholders' equity $19m
  • Short-term assets cover short-term liabilities $111m of assets due within a year against $13m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $111m short-term assets against $73m of longer-dated liabilities.
  • More cash than debt $20m of cash against $20m of debt.
  • Debt below 40% of shareholders' equity Debt is 106% of equity.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$58m of operating cash flow against $20m of debt.
  • Operating profit covers interest at least five times over No material interest expense reported.

From Orchestra Biomed Holdings, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: OBIO vs POCIOBIO vs RVPOBIO vs STXS

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Orchestra Biomed Holdings, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Orchestra Biomed Holdings, Inc.